IV Ketamine for Depression: Does Faster Mean Better?

What Is IV Ketamine Therapy for Depression?

IV ketamine therapy is an intravenous infusion of sub-anesthetic ketamine, given in a clinic to treat depression and treatment-resistant depression. Unlike SSRIs, which adjust serotonin signaling gradually over weeks, ketamine acts on the brain's glutamate system and can ease symptoms within hours to days. It has been an FDA-approved anesthetic since 1970 and on the WHO List of Essential Medicines since 1985²; its use for depression is off-label, prescribed at a clinician's discretion.¹⁰

The infusion delivers the entire dose directly into the bloodstream, so it produces the fastest onset and highest peak concentration of any ketamine route. That rapid, high peak is the reason the treatment is given in a clinic under monitoring rather than at home.

IV is one of several routes for delivering ketamine. Sublingual and intranasal forms deliver the same molecule but are absorbed more gradually, so they rise to a lower peak over a longer window than an IV dose does. Each route carries its own tradeoffs in setting, monitoring, and how intense the session feels.

• Route: intravenous infusion directly into the bloodstream
• Typical session: about 40 minutes for the active infusion
• Setting: in-clinic
• Monitoring: frequent vital-sign measurement by staff

Why IV Ketamine Acts Faster: A Fact About Delivery, Not Effectiveness

IV ketamine acts faster because the infusion places the entire dose into the bloodstream at once, with no absorption step in between, so the concentration in the blood climbs to its peak within minutes. Sublingual and oral ketamine have to pass through the lining of the mouth or the gut first, which spreads the same dose over a longer window and brings it to a lower peak. When researchers measured plasma concentrations across these routes, the IV curve rose fastest and highest while the absorbed routes rose later and lower (Yanagihara et al.).

That is a fact about delivery, not about effectiveness. How quickly a drug reaches its peak describes how it is delivered, not how well it works once it is active in the brain. The same holds for most medications: a faster route changes the shape of the concentration curve, not the size of the drug's effect. So the speed of IV onset, on its own, is not evidence of a stronger antidepressant result. It is evidence that the drug arrives all at once.

What a Higher Ketamine Peak Changes: Intensity, Not Outcome

A higher peak does change the ketamine experience, just not in the way the assumption suggests. It makes the subjective experience more intense and the body's physical response stronger, but the size of the antidepressant benefit does not rise along with it. How intense a session feels is a separate question from how much depression improves.

Why a Higher Peak Makes the Ketamine Experience More Intense

Intensity in this context refers to the strength of dissociative and perceptual effects you experience during a ketamine session.

The intensity of a session rises with the peak because the strength of the subjective effects tracks how much drug is in the blood at a given moment. Bowdle et al. measured this in healthy volunteers and found subjective effects scaled almost perfectly with plasma concentration (R = 0.93 to 0.99), and it is the parent ketamine molecule, not its metabolites, that drives that experience (Farmer et al.). A higher, faster peak therefore produces a more intense session, and a lower, slower peak a gentler one. The side effects of a session follow the same pattern, tied to high initial plasma levels and less pronounced on routes that peak lower (Schoevers et al.).⁶

But intensity is a feature of the experience, not a measure of the treatment. Some people want a more pronounced experience and some want a gentler one, and that is a real preference. It is simply a different question from how much a person's depression improves. A more intense session is not a more effective one.

Why the Intensity of IV Ketamine Requires In-Clinic Monitoring

IV ketamine is given in a clinic because its rapid, high peak puts more stress on the cardiovascular system, pushing blood pressure and heart rate up more sharply than a slower route would. That response has to be watched as it happens, so IV ketamine, like intranasal esketamine, is administered with staff monitoring vital signs and on hand to respond throughout the session (McIntyre et al.).

That added strain is a consequence of delivering the full dose at once, not a part of how ketamine treats depression. The body is put through more, but the antidepressant effect is no greater for it. A slower route reaches the same benefit without provoking the same cardiovascular response, which is why it can be supervised under a lighter framework, including structured at-home protocols. The clinic and the monitoring are the price of the high peak, not a sign of a better outcome.

Does Faster Onset Make IV Ketamine More Effective for Depression?

No. If the speed and height of ketamine's peak were what produced its antidepressant effect, IV would outperform slower routes by a wide margin. The published data shows the opposite: the largest real-world datasets for IV and for sublingual ketamine land in the same range on every standard measure.

The fair way to test this is to hold the measurement constant, using the same instrument (the PHQ-9) and the same point in treatment (the end of the induction course). On that basis, a sublingual at-home cohort of 11,441 clients (Mathai et al. 2024, Mindbloom's published study) and an in-clinic IV cohort of 537 patients (McInnes et al. 2022) report response, remission, and effect sizes that sit nearly on top of each other.

Each measures change within its own group, against the same instrument and the same endpoint. However, these are two separate real-world studies, not a single head-to-head trial, so they should be interpreted within the context of differences in design, patient population, and care setting.

Still, the pattern is unambiguous. The slower route, with its lower peak, reaches the same response rate, the same remission rate, and the same effect size as the faster one. If the rapid, high peak of IV were the active ingredient of recovery, that parity could not exist. The speed and height of the peak are not what produce the antidepressant result.

Why a Lower Ketamine Peak Does Not Mean Less Active Medicine

It is easy to assume a lower peak means a weaker dose, that sublingual or oral ketamine simply delivers less medicine than IV. It does not work that way. The part of the dose that does not show up as ketamine in the blood is not lost. The body converts much of it into norketamine, a related compound that is also active (Zanos et al.). So a lower peak does not mean less working medicine. It means the dose is carried in two active forms instead of mostly one, which is part of why slower routes reach the same outcomes as IV even with a lower peak.

How First-Pass Metabolism Converts Oral and Sublingual Ketamine Into Norketamine

When ketamine is swallowed or held under the tongue, it passes through the liver before reaching the rest of the body, and the liver converts much of it into norketamine on the way. This is called first-pass metabolism, and it is the reason oral and sublingual ketamine show a lower peak of ketamine than IV: a larger share of the dose has already become norketamine by the time it circulates.

The shift is large. With IV, the blood holds roughly equal amounts of ketamine and norketamine. With sublingual there is about four times as much norketamine as ketamine, and with oral, about seven times as much (Yanagihara et al.). So a lower peak of ketamine mostly reflects how much has turned into a second active compound, not medicine that was lost. For how much of each dose actually reaches the blood, see our companion guide on bioavailability.

IV Ketamine vs Esketamine vs At-Home Ketamine for Depression

IV, esketamine, and at-home sublingual ketamine are three ways to deliver closely related medicine. They differ mainly in where treatment happens, how much monitoring it takes, and their regulatory status, not in whether ketamine works for depression. Each fits a different set of needs.

IV ketamine is racemic ketamine delivered into the bloodstream in a clinic. Esketamine is a component of ketamine, its S-enantiomer, given as a nasal spray in a certified clinic under an FDA risk-management program (REMS). At-home ketamine is racemic ketamine, usually taken sublingually, in a person's home under remote clinical supervision.

IV may suit someone who wants a fully monitored clinical setting. Esketamine may suit someone who wants an FDA-approved option, has insurance coverage, and can attend a certified clinic. At-home sublingual may suit someone who does better in their own environment within a structured program.

These are different approaches for different needs, not a ranking. Where outcomes have been measured, supervised at-home sublingual and in-clinic IV land in the same range (Mathai et al.; McInnes et al.). FDA approval marks the regulatory path a product took to market, not a verdict that one route treats depression better than another.

Does Acting Faster Make IV Ketamine More Effective? The Bottom Line

No. Faster onset is real, but it describes how IV delivers the dose, not how well the dose treats depression. The rapid, high peak makes a session more intense and puts more strain on the body, which is why IV is given in a clinic under monitoring. None of that makes the antidepressant effect larger. The largest real-world datasets show a slower sublingual route reaching the same response, remission, and effect size as in-clinic IV, and a lower peak does not mean less medicine, because much of the dose is converted into active norketamine rather than lost. Faster describes the delivery. It does not describe the result.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.